Étiquette : ratio CBD-THC

Medicinal use of cannabis based products and cannabinoids, Tom P Freeman et al., 2019

Medicinal use of cannabis based products and cannabinoids Tom P. Freeman, Chandni Hindocha, Sebastian F. Green, Michael A. P. Bloomfield British Medical Journal, 2019, 365, l1141 doi : 10.1136/bmj.l1141   What you need to know • Cannabis based products for medicinal use contain cannabinoids derived from the cannabis plant, including Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination of THC and CBD. Synthetic cannabinoids for medicinal use typically mimic the effects of specific cannabinoids such as THC • THC is the constituent of cannabis that causes the “high,” whereas CBD is not intoxicating at typical doses. THC and CBD have contrasting mechanisms of action and therapeutic indications; THC [...]

Lire la suite

Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial, Daryl Efron et al.,

Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial Daryl Efron, Kaitlyn Taylor, Jonathan M Payne, Jeremy L Freeman, Noel Cranswick, Melissa Mulraney, Chidambaram Prakash, Katherine J Lee, Katrina Williams BMJ Open, 2020, 10, e034362. doi : 10.1136/bmjopen-2019-034362   Abstract Introduction : Severe behavioural problems (SBPs) are a common contributor to morbidity and reduced quality of life in children with intellectual disability (ID). Current medication treatment for SBP is associated with a high risk of side effects. Innovative and safe interventions are urgently needed. Anecdotal reports and preliminary research suggest that medicinal [...]

Lire la suite

Do medical cannabis growers attempt to produce cannabis with different cannabinoid concentrations than recreational growers?, Sharon R. Sznitman et al., 2019,

Do medical cannabis growers attempt to produce cannabis with different cannabinoid concentrations than recreational growers? Sharon R. Sznitman, Monica J. Barratt, Tom Decorte, Pekka Hakkarainen, Simon Lenton, Gary Potter, Bernd Werse and Chris Wilkins Drugs and Alcohol Today, 2019, 19, (4), 251-256, Doi : 10.1108/DAT-06-2019-0021   Abstract Purpose – It is conceivable that cannabis cultivators who grow for medical purposes aim to improve the therapeutic index of their cannabis by attempting to produce particular concentrations of CBD and/or THC. The purpose of this paper is to examine whether small-scalemedical cannabis growers differ fromthose growing for recreational reasons in terms of self-assessed concentrations of THC and CBD [...]

Lire la suite

Prescription of a THC/CBD-Based Medication to Patients with Dementia : A Pilot Study in Geneva, Barbara Broers et al., 2019

Prescription of a THC/CBD-Based Medication to Patients with Dementia : A Pilot Study in Geneva Barbara Broers, Zacharie Patà, Aline Mina, James Wampfler, Christian de Saussure, Sophie Pautex Medical Cannabis & Cannabinoids, 2019, 2, 56–59 Doi : 10.1159/000498924 Abstract Background : Dementia is increasing worldwide. No effective medication is currently available for the treatment of the underlying disease and accompanying behavioral symptoms. Cannabinoids might have a beneficial effect, but clinical studies with (low-dose) synthetic THC have not been conclusive. Objective : To test the acceptability, practical aspects, and clinical outcomes of the introduction of a THC/ CBD-based oral medication in severely demented patients in a specialized [...]

Lire la suite

Medical cannibus as an alternative for opioids for chronic pain : A case report, Franklin E. Caldera, 2020

Medical cannibus as an alternative for opioids for chronic pain : A case report Franklin E. Caldera SAGE Open Medical Case Reports, 2020, Volume 8, 1–3 DOI : 10.1177/2050313X20907015   Abstract Opioid medication–related deaths have increased to epidemic proportions in the last decade. This report describes a case of 43-year-old female with a traumatic brain injury who developed chronic pain and opioid dependence. The patient expressed concerns and wanted weaning off opioids. Recent legalization of medical marijuana in Pennsylvania allows us to try it as an alternative to opioids for chronic pain. Medical cannibus has risks associated with administration but is safer than opioids. Our patient [...]

Lire la suite

Mapping cannabis potency in medical and recreational programs in the United States, Mary Catherine Cash et al., 2020

Mapping cannabis potency in medical and recreational programs in the United States Mary Catherine Cash, Katharine Cunnane, Chuyin Fan, E. Alfonso Romero-Sandoval PLoS ONE, 2020, 15, (3), e0230167. Doi : 10.1371/journal.pone.0230167     Opinion d'expert: Les allégations sur l'infaisabilité du cannabis avec des concentrations élevées de THC à des fins médicales ne sont pas étayées par la science En mars 2020, le conseil d'administration de l'IACM a décidé d'installer une nouvelle catégorie dans le Bulletin de l’IACM, qui encourage à rédiger des opinions et des déclarations de chercheurs sur les rapports scientifiques actuels et des déclarations de collègues. Ces avis visent à stimuler la discussion sur [...]

Lire la suite

Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches, Marcel O. Bonn-Miller et al., 2018

Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches Marcel O. Bonn-Miller, Mahmoud A. ElSohly, Mallory J. E. Loflin, Suman Chandra and Ryan Vandrey International Review of Psychiatry, 2018, VOL. 30, NO. 3, 277–284 Doi : 10.1080/09540261.2018.1474730   ABSTRACT Accumulating evidence suggests that the endocannabinoid system is a promising target for the treatment of a variety of health conditions. Two paths of cannabinoid drug development have emerged. One approach is focused on developing medications that are directly derived from the cannabis plant. The other utilizes a single molecule approach whereby individual phytocannabinoids or novel cannabinoids with therapeutic potential are identified and synthesized for pharmaceutical [...]

Lire la suite

A cross-sectional examination of choice and behavior of veterans with access to free medicinal cannabis, Mallory J. E. Loflin et al., 2019

A cross-sectional examination of choice and behavior of veterans with access to free medicinal cannabis Mallory J E Loflin, Kimberly Babson, James Sottile, Sonya B Norman, Staci Gruber, and Marcel O Bonn-Miller The American Journal of Drug and Alcohol Abuse, 2019, VOL. 45, NO. 5, 506–513. Doi : 10.1080/00952990.2019.1604722   ABSTRACT Background : With a rise in public pressure to increase veteran access to medicinal cannabis, free cannabis collectives for military veterans are proliferating across the US. Objectives : The aim of the current study was to document which cannabis formulations and routes of administration are chosen by veterans with increased access to cannabis, and to determine [...]

Lire la suite

L’huile de chanvre contient-elle du THC et du CBD ?, Newsweed, 11 février 2020, Aurélien BERNARD

L’huile de chanvre contient-elle du THC et du CBD ? Newsweed, 11 février 2020 Aurélien BERNARD https://www.newsweed.fr/huile-chanvre-contient-thc-cbd/   L’huile de chanvre, extraite des graines, est une source précieuse d’omega 3 et 6 et de nutriments dans l’alimentation quotidienne. Sa valeur nutritionnelle et thérapeutique pourrait néanmoins aussi être attribuée à sa composition en cannabinoïdes qui, si faiblement présents, existent quand même. Dans une étude de 2019, plusieurs cannabinoïdes ont été détectés dans l’huile de graines de chanvre et permettent de déterminer des différences dans leur composition chimique. Bien que le CBDA et le CBD soient prédominants dans les dix huiles étudiées, 20 autres cannabinoïdes «mineurs» ont été [...]

Lire la suite

Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses, Will Lawn et al., 2016

Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses Will Lawn, Tom P. Freeman, Rebecca A. Pope, Alyssa Joye, Lisa Harvey, Chandni Hindocha, Claire Mokrysz, Abigail Moss, Matthew B. Wall, Michael A.P. Bloomfield, Ravi K. Das, Celia J.A. Morgan, David J. Nutt, H. Valerie Curran Psychopharmacology, 2016, 233, 3537–3552 Doi : 10.1007/s00213-016-4383-x   Abstract Rationale : Anecdotally, both acute and chronic cannabis use have been associated with apathy, amotivation, and other reward processing deficits. To date, empirical support for these effects is limited, and no previous studies have assessed both acute effects of Δ-9-tetrahydrocannabinol (THC) and [...]

Lire la suite